Selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2)

The major adduct formed by the food-borne carcinogen, PhIP with DNA

Novel human α-galactosidase A ligand, capable of stabilizing α-Gal A and restoring trafficking

Abundant lipid in the membranes of many algae, lower plants, and fungi, showing an inverse concentration relationship with phosphatidylcholine, being capable of replacing phosphatidylcholine

Novel HCV NS3 degrader, reducing susceptibility to resistance mutations, potently inhibiting HCV in a cellular infection model, exhibiting the most potent degradation (DC50 of 50nM at 4h) of HCV NS3,

Novel growth inhibitor of both triple-positive and triple-negative human breast cancer cell lines

Novel inducer of autophagic cell death through upregulation of HMGB1 in A549 cells

Novel Pim kinase inhibitor

The most potent inhibitor of sodium iodide symporter (NIS) reported to date

Novel potent, selective and covalent inhibitor of DCN1, selectively inhibiting neddylation of cullin 3 in cells

Novel STING agonist with enhanced binding to STING and cellular function, displaying strong anti-tumour activity

Novel potent and selective STING agonist, activating secretion of IFNβ, IL-6, TNF, and KC/GROα, exhibiting durable anti-tumour effects

Novel probe for protein S-sulfinylation from cells

Selective alpha4beta2 nAChR partial agonist for the treatment of nicotine dependence to assist in smoking cessation

Novel Inhibitor of the AAA-ATPase Drg1, blocking ribosome biogenesis

Histamine H1-receptor antagonist

Morin derivative, enhancing neural glyoxalase pathway (GP) activity and preventing methylglyoxal-mediated oxidative stress (OS) in an AD model

Major biliary metabolite of Diclofenac, a nonsteroidal antiinflammatory drug and COX inhibitor

Non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions

Selective herbicide for the control of dicot weeds

Lipophilic fluorescent reagent, labeling membranes and other hydrophobic structures

Natural Tat inhibitor, blocking HIV-1 transcription by specifically targeting the viral transactivator, Tat

Inhibitor of DTDST inhibitor, a novel intestinal epigallocatechin gallate (EGCg) transporter

Novel inhibitor of CP4H activity in cultured cells at concentrations that do not cause iron deficiency

Novel inhibitor of CP4H activity in cultured cells at concentrations that do not cause iron deficiency

Muscle relaxant, causing general central nervous system depression, relieving pain caused by strains, sprains, and other musculoskeletal conditions

Antiemetic agent used in the treatment of vomiting and vertigo

Agonist of the androgen receptor (AR); #333333; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans:

Corticosteroid Hormone Receptor Agonist

Novel dose-dependent inhibitor of the SARS-CoV-2 Mac1 Macrodomain

D1-like full agonist with similar affinity for D1 and D5, and roughly 10-fold selectivity over D2-like receptors

Competitive nicotinic receptor antagonist

Closely related co-metabolite of cyclosporin A

Unique antimigration and antiangiogenic agent

Novel lipid-based, high-density, environmentally sensitive (HIDE) probe

Novel lipid-based, high-density, environmentally sensitive (HIDE) probe

Vasodilator for the treatment of cardiopathy and renal disorders, acting as an adenosine reuptake inhibitor.

Building Block

Building Block

Novel inhibitor of AMA1-RON2 interaction, blocking merozoite invasion from schizont-infected RBCs; Antidepressant; Acetylcholinesterase inhibitor

Serotonin antagonist and histamine antagonist

Novel analog of etomidate, potently inhibiting 11-beta-hydroxylase without GABAA receptor positive modulatory and sedative-hypnotic activities

Anti-infective agent against certain protozoa such as Babesia, Trypanosoma, Cytauxzoon, and certain bacteria including Brucella and Streptococcus

Inhibitor of Topoisomerase>DNA topoisomerase II; very potent cytotoxic antitumor agent

Long-lasting prodrug of nalbuphine, acting as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor and as a high-efficacy partial agonist of the κ-opioid receptor

Natural full D1 dopamine receptor agonist

Potent antagonist of GABA A receptors that contain alpha1 and beta2 subunits

Novel activator of the bone marker alkaline phosphatase (ALP), markedly promoting osteoblast differentiation, including expression of Runx2, Osterix, and Osteocalcin, mediating osteogenesis through activation of p38-β

Novel negative allosteric modulator of the mGlu5 receptor

Inhibitor of ATPase activity of HSP70

Antibiotic, specifically inhibiting the initiation of RNA synthesis, binding isohelically to the minor groove of B-DNA at A/T rich sites

Parasympathomimetic with longer duration of action

Novel selective Factor Xa inhibitor, reducing thrombus formation with low risk of bleeding

Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line

Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line

Inhibitor of NF-kappaB-mediated GROalpha expression, suppressing the TNFalpha-induced invasive capability of MDA-MB-231 human breast cancer cells

Novel autophagonizer, inducing autophagic cell death in apoptosis-defective cell line

Novel acetylcholinesterase inhibitor, promoting synaptic function and neuronal survival, ameliorating cognitive deficits in SAMP8 mice via improved mitochondrial dynamics and increased activity of the NMDAR-CREB-BDNF pathway

Novel potent anti-MRSA agent, disrupting biofilms with no resistance development, sensitizing rifampicin and tetracycline against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

Specific protein disorder catalyzer of HIV-1 Nef

Competitive inhibitor of both SPHK1 and SPHK2

Ultrasensitive bioluminogenic enzyme substrate

Chromogenic peptide substrate, being highly sensitive for the measurement of activated Protein C.

Prodrug of CPPTL, inducing apoptosis in a dose-dependent manner via the ROS/JNK pathway in acute myeloid leukemia

Novel multi-target anticancer prodrug activated by the tumor specific CYP1B1 enzyme, potently inhibiting HCT-15, HCT-116 and K562 cells growth, showing moderate anti-proliferative activity towards MDA-MB-231, HepG2, PANC, Bel7402 and MGC803 cancer cells,

Novel antineoplastic agent, exhibiting remarkable anticancer activity as well as excellent cellular selectivity

Novel blocker of the TLR2 and TLR4 downstream signaling pathway, effectively inhibiting mRNA expression of MyD88 and p65, major subunit of nuclear factor-kappaB

Novel non-nucleoside inhibitor of Zika viral RNA-dependent RNA polymerase (RdRp) enzymes

Novel potent and selective PROTAC degrader of myeloid cell leukemia 1 (MCL1)

Novel cell permeable caged Luciferin

Novel inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells

Potent and highly selective µ opioid agonist

Novel,orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor

Novel DNA primase inhibitor

Novel DNA primase inhibitor

Novel potentiator of β-lactam activity against Gram positive and Gram negative pathogens

Novel antitubercular and antiparasitic agent, possessing excellent in vitro activity against both L. donovani and Leishmania infantum as well as displaying a better safety profile

Analeptic agent, stimulating central nervous system; Anti-barbiturate-overdose

Highly potent cytotoxic microtubule inhibitor

Selective MAO-B inhibitor

Dual orexin receptor antagonist (OX1R and OX2R antagonist or DORA)

Anthelmintic, for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle

Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects

Agonist of GABAA receptors α15 subunits

Novel antibacterial with activity against the Gram-negative bacteria associated with nosocomial infections

Novel effective and selective inhibitor of E. coli topoisomerase I

Novel 2-aminoethyl diphenylborinate (2-APB) analogue, inducing a profound activation of SOCE in DT40 cells, albeit at low concentrations (10 nM), blocking the melatonin-induced [Ca ] cyt increase and SOCE in P. falciparum.

Novel boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors

Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP

First Potent Small Molecule Ligand for MALAT1

Novel highly selective agonist for the δ-opioid receptor, producing less convulsions than most drugs from this family and having antidepressant-like effects

Novel inhibitor of dipeptidyl peptidase 7 (DPP7)

Novel selective DPP8/9 inhibitor, blocking AML progression in vivo

Substrate of CYP3A and inhibitor of P-glycoprotein

Novel DprE1 inhibitor, killing M. tuberculosis

Click chemistry tool molecule in probing peptidoglycan (PG)

Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP

Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV

Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV

Oral non-opioid anti-tussive agent for treatment of cough

Inhibitor of the growth of estrogen receptor-presenting breast cancers

Novel potent PTHR1 antagonist

Novel selective PPARγ modulator, resulting in robust plasma glucose reductions with excellent DMPK profiles

Novel potent orally active hepcidin production inhibitor

Novel and orally bioavailable PTHR1 antagonist

Novel non-macrolide GPR38 agonist

Novel potent orally active hepcidin production inhibitor

Novel Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease

Pathogen motility inhibitor of EcDsbA

Non-toxic human papillomavirus E6 inhibitor

Novel Plasmodium falciparum Dihydroorotate Dehydrogenase (PfDHODH) Inhibitor (Pfalcip cells: 0.0018 μM)

Novel potent inhibitor of dihydroorotate dehydrogenase (DHODH)

Novel potent Dihydroorotate Dehydrogenase (DHODH) inhibitor

Novel selective mGlu5 receptor negative allosteric modulator (NAM) with potent antidepressant and antimanic activity

Agonist of S1P receptors

Novel potent and orally active activator of PP2A

Negative control for DT2216

Potent and selective degrader of mutant FKBP12F36V fusion proteins

Antiviral agent against influenza A, parainfluenza Sendai, coxsackie A21, and rhinovirus

Irreversible DNA minor groove binding alkylating agent, disrupting the nucleic acid architecture and leading to tumor cell death

Anthracycline antibiotic from Streptomyces

Selective 5-HT2A receptor antagonist

Potent and selective 5-HT 2A receptor antagonist

Novel potent and highly selective inhibitor of VEGFR, exhibiting antitumor activities both in vitro and in vivo.

Novel and potent leukotriene B(4) receptor antagonist

Novel Hsp70 agonist, showing no cellular toxicity and induced cellular stress response pathways

Novel allosteric inhibitor of the tumor-promoting interaction between the oncogenic factor AIMP2-DX2 and HSP70

Antitumor antibiotic

Novel Selective and Potent EGFR Inhibitor, Overcoming T790M-Mediated Resistance in Non-Small Cell Lung Cancer

Novel potent Inhibitor of PI3Kalpha

Novel OPG/RANKL upregulator, increasing OPG expression without affecting RANKL expression, promoting osteoblast differentiation while inhibiting osteoclast differentiation, regulating OPG expression through canonical Wnt/β-catenin signaling

γ-Secretase modulator (GSM) photoaffinity probe, revealing distinct allosteric binding sites on presenilin

Potent Activator of P53-Independent Cellular Senescence

Novel XIAP BIR2 domain-binding degrader of E3 ubiquitin ligases

Sigma1 receptor ligand and potential atypical antipsychotic

Novel degrader of GST-α and GST-α-EGFP fusion proteins as well as endogenous GST-π in cells and lysates

Highly potent and selective activator of isozymes CA-VA and CA-VII

Highly potent and selective activator of isozymes CA-VA and CA-VII

Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist

Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties

Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis

Novel EBV activator, well-performing EBV lytic cycle inducer

Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme

Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria

Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle

Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders

An impurity of Edoxaban, a novel inhibitor of factor Xa

Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways

Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity

Calcium channel blocker, blocking both T-type and L-type calcium channels

Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo

Antibiotic, inhibiting bacterial protein synthesis

Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer

Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis

Novel EGFR inhibitor, significantly reducing myocardial inflammation, fibrosis, apoptosis, and dysfunction, showing promises to the treatment on obesity-induced cardiac complications

Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis

Potent inhibitor of adrenergic alpha1, alpha2c, 5-HT2a, 5HT7 receptors; Relatively selective blocker of adrenergic alpha2c over adrenergic alpha2a receptors.

Selective, non-competitive AMPA receptor antagonist, improving motor co-ordination

Antibacterial agent

Arginase Inhibitor, activating EPO-mediated mitochondrial function and haemoglobin expression, stimulating melanogenesis by MAP kinase activation and tyrosinase upregulation

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

Novel Mirk kinase inhibitor, inhibiting DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites, blocking the in vivo growth of pancreatic cancer cells

Novel water-soluble analog of progesterone

Novel water-soluble analog of progesterone, reducing cerebral edema and lesion size and improving functional recovery, decreasing glial fibrillary acidic protein expression immunoreactivity

Novel RNA-competitive, ATP-uncompetitive eIF4A Inhibitor, decreasing BJAB Burkitt lymphoma cell viability, engaging a novel pocket in the RNA groove of eIF4A and inhibiting unwinding activity by interfering with proper RNA binding and suppressing ATP hydr

Novel anti-bacterial agent, targeting the MmpL3 transporter in Mycobacterium abscessus

Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase

Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase

Novel etomidate analogue, enhancing GABA A receptors currents with a concentration for 50% of maximal effect (EC 50 ) of 0.98 {plus minus} 0.02 μM, which was about three times more potent than etomidate (3.07 {plus minus} 1.67 μM), retaining the favorable

Novel inhibitor of Aurora B kinase

Novel ligand of the apelin receptor (APJ), possessing high affinity for APJ (Ki 4.6 nM) and producing cardiorenal effects in vivo similar to those of ELA

Oleoylethanolamide-modelled PPAR

Novel γ-secretase inhibitor

Novel highly potent, selective, and CNS-penetrant inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme

Eukaryotic Ribosomal Selective Glycoside (ERSG), inducing read-through of premature stop codons (PSCs) and resulting in translation of full-length protein

Novel BCL-2 inhibitor, neutralizing the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitizing BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine

High affinity ligand for estrogen receptor-

Novel potent antitumor agent, inducing apoptosis in a panel of tumor cell lines

Novel potent and highly selective c-Met inhibitor

PDE 3 inhibitor

Non-peptide angiotensin II receptor antagonist

Novel peptide endomorphin (EM) degradation blocker

Novel peptide endomorphin (EM) degradation blocker

Novel peptide endomorphin (EM) degradation blocker

Novel corticotropin-release factor 1 antagonist

5-FU derivative, with various anticancer agents against human cancer xenografts

Novel PRMT inhibitor, preventing arginine methylation of cellular proteins, being essentially inactive against the lysine methyltransferase SET7/9

Novel Potent and Selective Inhibitor of Protein Arginine Methyltransferase 4 (PRMT4)

Antioxidant, inhibiting free radical oxidation of biomembrane lipids, modulating the activity of membrane-bound enzymes and the receptor complexes of the brain membranes

Novel non-steroidal CYP17 inhibitor. reducing androgen synthesis for treatment of castration-resistant prostate cancer

Novel butyrylcholinesterase inhibitor against Alzheimer's disease

Novel Potentiator of α7 Receptor Signaling

Useful pharmceutical building block

Antimalarial

Natural vesicle trafficking inhibitor

Specific inhibitor of trafficking pathways, disrupting recycling at the PM via interference with ROP6/RIC1 signalling

Novel inhibitor of eukaryotic ARF-GEFs (ADP-ribosylation factor guanine nucleotide exchange factors)

Specific inhibitor for plant callose deposition during cytokinesis without affectting endomembrane trafficking during interphase or cytoskeletal organization